NCT00103337View on ClinicalTrials.gov

Cilengitide in Treating Patients With Metastatic Prostate Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

106

Participants

Timeline

Start Date

January 31, 2005

Primary Completion Date

October 31, 2007

Conditions
Recurrent Prostate CancerStage IV Prostate Cancer
Interventions
DRUG

cilengitide

Given IV

OTHER

laboratory biomarker analysis

Correlative studies

Trial Locations (1)

48109

University of Michigan University Hospital, Ann Arbor

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00103337 - Cilengitide in Treating Patients With Metastatic Prostate Cancer | Biotech Hunter | Biotech Hunter